135 related articles for article (PubMed ID: 15860861)
1. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia.
Wu S; Gessner R; Taube T; von Stackelberg A; Henze G; Seeger K
J Clin Oncol; 2005 May; 23(13):3038-42. PubMed ID: 15860861
[TBL] [Abstract][Full Text] [Related]
2. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence.
Wu S; Gessner R; von Stackelberg A; Kirchner R; Henze G; Seeger K
Cancer; 2005 Mar; 103(5):1054-63. PubMed ID: 15651075
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
4. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia.
Kirschner-Schwabe R; Lottaz C; Tödling J; Rhein P; Karawajew L; Eckert C; von Stackelberg A; Ungethüm U; Kostka D; Kulozik AE; Ludwig WD; Henze G; Spang R; Hagemeier C; Seeger K
Clin Cancer Res; 2006 Aug; 12(15):4553-61. PubMed ID: 16899601
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
6. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
8. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.
Cario G; Izraeli S; Teichert A; Rhein P; Skokowa J; Möricke A; Zimmermann M; Schrauder A; Karawajew L; Ludwig WD; Welte K; Schünemann HJ; Schlegelberger B; Schrappe M; Stanulla M
J Clin Oncol; 2007 Oct; 25(30):4813-20. PubMed ID: 17947730
[TBL] [Abstract][Full Text] [Related]
9. Expression of interleukin 15 in primary adult acute lymphoblastic leukemia.
Wu S; Fischer L; Gökbuget N; Schwartz S; Burmeister T; Notter M; Hoelzer D; Fuchs H; Blau IW; Hofmann WK; Thiel E
Cancer; 2010 Jan; 116(2):387-92. PubMed ID: 19924795
[TBL] [Abstract][Full Text] [Related]
10. Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse.
Wu S; Gessner R; Taube T; Korte A; von Stackelberg A; Kirchner R; Henze G; Seeger K
J Pediatr Hematol Oncol; 2006 Apr; 28(4):216-20. PubMed ID: 16679918
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
Stachel D; Albert M; Meilbeck R; Kreutzer B; Haas RJ; Schmid I
Eur J Med Res; 2006 Mar; 11(3):102-13. PubMed ID: 16751110
[TBL] [Abstract][Full Text] [Related]
12. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
14. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
Reismüller B; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Dieckmann K; Henze G; Haas OA; Gadner H; Mann G;
Br J Haematol; 2009 Feb; 144(4):559-70. PubMed ID: 19077160
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia.
Sauerbrey A; Häfer R; Zintl F; Volm M
Anticancer Res; 1999; 19(1B):645-9. PubMed ID: 10216470
[TBL] [Abstract][Full Text] [Related]
17. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
18. Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.
Hoffmann K; Firth MJ; Beesley AH; Freitas JR; Ford J; Senanayake S; de Klerk NH; Baker DL; Kees UR
Br J Haematol; 2008 Mar; 140(6):656-64. PubMed ID: 18302714
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
Schrappe M
Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
